Innovation is at the heart of everything we do.
Our proprietary antigen discovery platform is the cornerstone of our approach to developing next-generation cancer immunotherapies. It represents a seamless integration of advanced bioinformatics with immunopeptidomics, designed to fuel downstream cellular engineering.
Get In Touch
Mining the Genomic Space
Our process begins with a deep dive into the genomic and epigenomic landscape. Through sophisticated bioinformatic analysis, we mine vast data to identify potential antigens—unique markers on cancer cells that can be targeted by the immune system. This initial step is crucial in uncovering the specific vulnerabilities of cancer cells, setting the stage for the development of highly targeted therapies.
Antigen Validation
Once potential antigens are identified, our process couples bioinformatic insights with cutting-edge surfaceomics and immunopeptidomics data. This integrated approach allows us to directly identify actionable targets, ensuring that our therapies are designed to hit the most relevant and impactful antigens.
Cellular Engineering
The knowledge gained from our antigen discovery phase feeds directly into the next critical step: cell development. We are able to discover and engineer receptors that are optimally suited to target the identified antigens. Whether it’s T cells, NK cells, or innate immune cells, we leverage the full spectrum of immune system components to create powerful, customized therapies designed to combat cancer with precision.
From Discovery to Treatment
By combining the best of bioinformatics, proteomics, and cell engineering, we are creating cell therapies of tomorrow.